First AD

Second AD

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

Factors for Selecting a BTK Inhibitor vs Other Regimens in CLL

Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

Real-World Use of BTK Inhibitors in Chronic Lymphocytic Leukemia

OncLive News Network®

Fred Hutch Cancer Center

Cancer Centers

Partner

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

Translating BTK Inhibitor Data into Clinical Decision-Making

The SEQUOIA Trial of Zanubrutinib vs BR in Previously Untreated CLL/SLL

Matching-Adjusted Indirect Comparisons of BTK Inhibitors in CLL

Real-World Safety Data for BTK Inhibitors in CLL from EHA 2024

Future Treatment Directions and Ongoing Trials in CLL